ALNY vs. LLY: Alnylam Pharmaceuticals vs. Eli Lilly Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while LLY is classified in Pharmaceuticals.
| Profile Item | ALNY | LLY |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 20.89 billion USD | 1,206.07 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2004 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | LLY |
|---|---|---|
| Total Return (1Y) | -64.57% | 52.36% |
| Total Return (3Y, Annualized) | -1.58% | 34.18% |
| Total Return (5Y, Annualized) | -3.13% | 41.08% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | LLY |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 35.34% |
| Beta (5Y) | 0.45 | 0.40 |
| Max Drawdown (5Y) | -68.25% | -34.48% |
| Avg. Volume (3M) | 1.90M | 2.52M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | LLY |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 1.36 |
| Sortino Ratio (1Y) | -1.45 | 2.29 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Eli Lilly (LLY) at 86.02% also sits in the top quartile.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
86.02%
- Max
- 109.18%
- LLY
- 86.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Eli Lilly (LLY) at 31.90% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.90%
- LLY
- 31.90%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
53.66%
- Max
- 83.12%
- LLY
- 53.66%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | LLY |
|---|---|---|
| ROE (TTM) | 138.07% | 86.02% |
| ROA (TTM) | 9.51% | 21.06% |
| Net Margin (TTM) | 52.85% | 31.90% |
| Operating Margin (TTM) | 23.72% | 53.66% |
| Gross Margin (TTM) | 77.28% | 83.63% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Eli Lilly (LLY) at 44.70% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: Eli Lilly (LLY) reports EPS growth of 95.99%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | LLY |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 44.70% |
| Revenue Growth (3Y CAGR) | 52.98% | 31.69% |
| EPS Growth (YoY) | -- | 95.99% |
| EPS Growth (3Y CAGR) | -- | 51.71% |
Financial Strength
Current Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- LLY
- 1.39
- Min
- 0.10
Debt / Equity (MRQ)
Both Alnylam Pharmaceuticals (ALNY) at 0.83 and Eli Lilly (LLY) at 1.23 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.23
- Max
- 1.42
- LLY
- 1.23
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | LLY |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 1.39 |
| Debt / Equity (MRQ) | 0.83 | 1.23 |
| Net Debt / EBITDA | -0.57 | 0.96 |
Dividends
Dividend Yield (TTM)
Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.49%
- LLY
- 0.49%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.71%
- LLY
- 21.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.49% |
| Dividend Payout Ratio (TTM) | 0.00% | 21.71% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.95
- Max
- 85.34
- LLY
- 43.95
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.95
- Max
- 58.18
- Q3
- 25.77
- LLY
- 13.95
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 5.79 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.96
- LLY
- 29.96
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | LLY |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 43.95 |
| P/S Ratio (TTM) | 4.17 | 13.95 |
| P/B Ratio (MRQ) | 5.79 | 29.96 |
| Free Cash Flow Yield (TTM) | 1.57% | 0.77% |